{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:34:53Z","timestamp":1789425293506,"version":"build-2803163510"},"reference-count":26,"publisher":"Oceanside Publications Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Real-life studies have shown the effects of biologic therapies on severe asthma. However, evidence for discontinuing treatment after targeted improvement remains limited.  <jats:bold>Objective:<\/jats:bold> This study investigated the factors associated with clinical\n remission in patients with severe asthma treated with biologics and explores physician decision-making with regard to the continuation or discontinuation of treatment after remission.  <jats:bold>Method:<\/jats:bold> A retrospective analysis was conducted on 65 patients with severe asthma who received\n biologics for at least 12 months between 2012 and 2024. Demographic and clinical data were reviewed, alongside physician-reported reasons for continued biologic use after remission and outcomes after treatment discontinuation.  <jats:bold>Results:<\/jats:bold> Clinical remission was achieved in\n 44.6% of the patients. Patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease, allergic bronchopulmonary aspergillosis, or eosinophilic granulomatosis with polyangiitis, and those with waning effect did not discontinue biologics after remission due to physician judgment\n and concerns about exacerbating both asthma and coexisting conditions. The decision to continue biologic therapy after remission was influenced by nasal polyposis, intermittent use of high-dose inhaled corticosteroids, previous failed cessations, and certain other factors. Of the 13 patients\n who discontinued biologic treatment, 3 did so due to biologic nonresponse, all 3 with asthma\u2010chronic obstructive pulmonary disease overlap (ACO). Ten had achieved clinical remission before discontinuation. Treatment was restarted in one of these 10 patients due to exacerbations and\n loss of symptom control. Nonsevere exacerbations occurred in two of the remaining nine patients.  <jats:bold>Conclusion:<\/jats:bold> Biologics are highly effective in achieving remission in severe asthma. Achieving the desired goals does not require continuity of biologics in all patients. Attention\n to waning symptoms may contribute to the success of drug discontinuation. Individualized treatment plans, including consideration of comorbidities, adjustments in dose intervals, and nonbiologic treatment options, are essential for optimal outcomes with regard to cessation of biologics.<\/jats:p>","DOI":"10.2500\/aap.2025.46.250023","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:34:02Z","timestamp":1751934842000},"page":"287-295","source":"Crossref","is-referenced-by-count":4,"title":["Biologic treatment discontinuation in severe asthma: A real-life study on factors influencing clinical remission and physician decision-making"],"prefix":"10.2500","volume":"46","author":[{"given":"Tugba","family":"Onalan","sequence":"first","affiliation":[{"name":"From the Division of Clinical Immunology and Allergy, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Colkesen","sequence":"additional","affiliation":[{"name":"From the Division of Clinical Immunology and Allergy, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Arzu","family":"Akkus","sequence":"additional","affiliation":[{"name":"From the Division of Clinical Immunology and Allergy, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Emin","family":"Gerek","sequence":"additional","affiliation":[{"name":"From the Division of Clinical Immunology and Allergy, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filiz Sadi","family":"Aykan","sequence":"additional","affiliation":[{"name":"From the Division of Clinical Immunology and Allergy, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevket","family":"Arslan","sequence":"additional","affiliation":[{"name":"From the Division of Clinical Immunology and Allergy, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2500\/aap.2020.41.200015","article-title":"Biologics for oral corticosteroid-dependent asthma","volume":"41","author":"Y\u0131lmaz","year":"2020","journal-title":"Allergy Asthma Proc"},{"key":"B4","doi-asserted-by":"crossref","first-page":"e20230405","DOI":"10.36416\/1806-3756\/e20230405","article-title":"Clinical remission after biologic therapy discontinuation in pediatric patients with severe asthma: a case series from a tertiary center","volume":"50","author":"Castelli","year":"2024","journal-title":"J Bras Pneumol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1080\/02770903.2021.1971700","article-title":"Factors leading to discontinuation of biologic therapy in patients with severe asthma","volume":"59","author":"Silver","year":"2022","journal-title":"J Asthma"},{"key":"B6","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2147\/JAA.S340684","article-title":"Feasibility of discontinuing biologics in severe asthma: an algorithmic approach","volume":"14","author":"Hamada","year":"2021","journal-title":"J Asthma Allergy"},{"key":"B7","doi-asserted-by":"crossref","first-page":"107416","DOI":"10.1016\/j.rmed.2023.107416","article-title":"The perceived waning of biologics in severe asthma","volume":"219","author":"Kroes","year":"2023","journal-title":"Respir Med"},{"key":"B8","doi-asserted-by":"crossref","first-page":"1753466618805662","DOI":"10.1177\/1753466618805662","article-title":"Asthma-COPD overlap: identification and optimal treatment","volume":"12","author":"Cos\u00edo","year":"2018","journal-title":"Ther Adv Respir Dis"},{"key":"B9","doi-asserted-by":"crossref","first-page":"2102483","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: what is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur Respir J"},{"key":"B10","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2213-2600(23)00230-8","article-title":"2023 GINA report for asthma","volume":"11","author":"Venkatesan","year":"2023","journal-title":"Lancet Respir Med"},{"key":"B12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejim.2024.10.015","article-title":"Chronic obstructive pulmonary disease's eosinophilic phenotype: clinical characteristics, biomarkers and biotherapy","volume":"131","author":"Maniscalco","year":"2025","journal-title":"Eur J Intern Med"},{"key":"B13","article-title":"Asthma and COPD overlap","volume-title":"StatPearls [Internet]","author":"Awad","year":"2025"},{"key":"B14","first-page":"212","article-title":"Effects of dupilumab for asthma\u2013chronic obstructive pulmonary disease overlap","volume":"22","author":"Kodaka","year":"2023","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3390\/medicina60030448","article-title":"The effectiveness of biological agents on chronic rhinosinusitis with nasal polyposis in patients with comorbid asthma: a multicenter real-life study from T\u00fcrkiye","volume":"60","author":"Demir","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"B16","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jaci.2020.01.020","article-title":"Biologics for chronic rhinosinusitis with nasal polyps","volume":"145","author":"Bachert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2500\/aap.2021.42.210080","article-title":"Treatment options for chronic rhinosinusitis with nasal polyps","volume":"42","author":"Wallace","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"B18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jaci.2018.10.037","article-title":"New delivery forms of nasal corticosteroids","volume":"143","author":"Fokkens","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1016\/j.jaip.2023.09.007","article-title":"Another therapy for chronic rhinosinusitis with nasal polyps","volume":"11","author":"Dokmeci","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B20","first-page":"00365-X","article-title":"The combination of allergen immunotherapy and biologics for inhalant allergies: exploring the synergy","volume":"S1081-1206","author":"Olivieri","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.anai.2023.05.016","article-title":"Aspirin-exacerbated respiratory disease: updates in the era of biologics","volume":"131","author":"Mullur","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/ACI.0000000000000875","article-title":"Biologics for eosinophilic granulomatosis with polyangiitis","volume":"23","author":"Caminati","year":"2023","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00408-024-00717-y","article-title":"Efficacy of biologics in patients with allergic bronchopulmonary aspergillosis: a systematic review and meta-analysis","volume":"202","author":"Chen","year":"2024","journal-title":"Lung"},{"key":"B24","doi-asserted-by":"crossref","first-page":"1413233","DOI":"10.3389\/fimmu.2024.1413233","article-title":"Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients","volume":"15","author":"L\u00f3pez","year":"2024","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1080\/21645515.2020.1753440","article-title":"Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab","volume":"16","author":"Ridolo","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"B26","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","article-title":"Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma","volume":"170","author":"Djukanovi\u0107","year":"2004","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2025\/00000046\/00000004\/art00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T04:32:47Z","timestamp":1752553967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2025.46.250023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7,1]]}},"alternative-id":["1088-5412(20250701)46:4L.287;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2025.46.250023","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}